Norwegian University of Science and Technology
ntnu.eduTotal trials
488
Active
68
Phase 3
20
Total enrollment
145,799
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 31 of 31 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Botulinum Toxin Type A | — | — | — | — | 5 | ||
| Atezolizumab | — | — | — | — | — | 1 | |
| ExPlas | — | — | — | — | — | 1 | |
| Octaplasma | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Blood samples | — | — | — | — | — | 2 | |
| Ibuprofen | — | — | — | — | 3 | ||
| Candesartan | — | — | — | — | 2 | ||
| Gabapentin | — | — | — | — | — | 1 | |
| Chlorprothixene | — | — | — | — | — | 1 | |
| Multidisciplinary treatment | — | — | — | — | — | 1 | |
| Treatment as usual | — | — | — | — | — | 1 | |
| Valsartan | — | — | — | — | — | 1 | |
| Fecal samples | — | — | — | — | — | 1 | |
| Buprenorphine | — | — | — | — | — | 1 | |
| Enalapril | — | — | — | — | — | 1 | |
| Irbesartan | — | — | — | — | — | 1 | |
| Amlodipine | — | — | — | — | — | 1 | |
| Losartan | — | — | — | — | — | 1 | |
| Quetiapine | — | — | — | — | — | 1 | |
| Escitalopram | — | — | — | — | — | 1 | |
| Paracetamol | — | — | — | — | — | 1 | |
| Venlafaxine | — | — | — | — | — | 1 | |
| Apixaban | — | — | — | — | — | 1 | |
| Lercanidipine | — | — | — | — | — | 1 | |
| Stool samples | — | — | — | — | — | 1 | |
| Lamotrigine | — | — | — | — | — | 1 | |
| Hydrochlorothiazide | — | — | — | — | — | 1 | |
| Ramipril | — | — | — | — | — | 1 | |
| Fluoxetine | — | — | — | — | — | 1 | |
| Metoprolol | — | — | — | — | — | 1 |
Next readouts
- 2024-04-01
- 2024-11-10
- 2025-09
- 2026-05
- 2026-10
- 2026-10
- 2026-10
- 2026-10
- 2026-10
- 2026-10
Top conditions
- Obesity, Morbid31
- Obesity30
- Stroke10
- Mental Disorders9
- Cardiovascular Diseases9
- Polycystic Ovary Syndrome8
- Pain8
- Atrial Fibrillation8
Frequently asked questions about Norwegian University of Science and Technology
- How many clinical trials does Norwegian University of Science and Technology have on ClinicalTrials.gov?
- Norwegian University of Science and Technology is listed as the lead sponsor on 488 clinical trials in ClinicalTrials.gov, 68 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Norwegian University of Science and Technology's trials are in Phase 3?
- 20 of Norwegian University of Science and Technology's trials are in Phase 3, spread across 31 active drug programs.
- What therapeutic areas does Norwegian University of Science and Technology focus on?
- Norwegian University of Science and Technology's most-studied conditions on ClinicalTrials.gov are Obesity, Morbid, Obesity, Stroke, Mental Disorders, Cardiovascular Diseases.
- When are Norwegian University of Science and Technology's next clinical trial readouts?
- Norwegian University of Science and Technology has 10 upcoming primary-completion readouts tracked here; the soonest is “Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer”, expected around 2024-04-01.